New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
15:34 EDTPSUN, VCYT, RENN, ORCL, SCTY, ADBENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Oracle (ORCL), consensus 70c; Adobe (ADBE), consensus 25c; SolarCity (SCTY), consensus (55c); Renren (RENN), consensus (4c); Veracyte (VCYT), consensus (38c); Pacific Sunwear (PSUN), consensus (19c).
News For ORCL;ADBE;SCTY;RENN;VCYT;PSUN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 27, 2015
14:47 EDTORCLAnalysts debate Workday after post-earnings selloff
Last night's results and guidance from Workday (WDAY) prompted a selloff in the stock a several cautious notes from research firms. However, multiple analysts remain bullish on the company and see strong prospects hidden behind the "relatively conservative" guidance. WHAT'S NEW: After the market close on Tuesday, Workday reported first quarter losses per share of (2c) on revenues of $251M, both of which beat consensus estimates. However, the company's second quarter revenue guidance of $270M-$274M bracketed the consensus forecast of about $272M. ANALYST REACTIONS: Brean Capital's Sarah Hindlian noted that traders were likely disappointed by the lack of major client announcements for Workday's FMS product, but said she believes FMS will be successful in the long term. Hindlian added that she expects Workday to become a "clear winner" eventually, but warned of a significant correction in the stock and noted that "significant" R&D spending is required before the company can capture the full market and she reiterates a Hold rating on the stock. Jefferies' John DiFucci and Brad Zelnick were less hopeful, saying the company's 31% billings growth versus 69% last year reflects "very aggressive" competition from Oracle (ORCL) and SAP (SAP), which could signal lessened momentum for Workday. The firm believes renewals may be a bright spot for the company going forward, but kept a Hold rating on the stock and cut its price target to $92 from $99 on the shares. Wells Fargo's Jason Maynard said the company's "relatively conservative" guidance is likely due to some lag in large deal signings as well as a relatively slow acceleration in Europe. The firm lowered its price target to $105-$110 from $110-$120, but remained optimistic on Workday, citing "extremely strong" renewals, new client wins in human capital management, and a maturing financial product. Richard Davis and David Hynes from Canaccord lowered Workday's price target to $100 from $110, but nevertheless said they believe the company faces a "decade of growth." The firm was not surprised at the recent selloff and recommended using weakness in the stock price to fill out investment positions in Workday. PRICE ACTION: Workday is down over 10% to about $83 per share in afternoon trading. Oracle and SAP are up roughly 1.8% and 1%, respectively.
06:27 EDTORCLUS administration backs Oracle in Google case, Financial Times reports
Subscribe for More Information
05:20 EDTORCLJefferies cuts Workday price target on moderating growth
Subscribe for More Information
May 26, 2015
06:38 EDTORCLMicrosoft buying Salesforce 'makes a lot of sense,' says Piper Jaffray
Subscribe for More Information
May 22, 2015
10:03 EDTRENNHigh option volume stocks
High option volume stocks: HBB RENN ONTY LGF JMEI DK JO INTU TFM
May 21, 2015
19:51 EDTSCTYSolarCity CEO says Tesla Battery works with solar homes
Subscribe for More Information
16:54 EDTVCYTVeracyte files to sell 4.9M shares of common stock for holders
Subscribe for More Information
08:15 EDTORCLSalesforce acquisition still possible, says JMP Securities
After Salesforce reported stronger than expected results, JMP Securities indicated that the results, along with statements by the company's CEO, make an acquisition seem less likely. However, the firm continues to believe that Google (GOOG), Oracle (ORCL), or Microsoft (MSFT) could buy the company. All three potential acquirers have significant cash and strong potential synergies with Salesforce, and the world is moving to the cloud, the firm explained. It raised its price target on Salesforce to $80 from $75 and keeps an Outperform rating on the shares.
06:37 EDTORCLOracle to cut 40% of industry solutions team, Business Insider reports
Subscribe for More Information
May 20, 2015
15:32 EDTVCYTVeracyte reports positive data on company's molecular classifier
Subscribe for More Information
07:36 EDTADBEJPMorgan to hold a conference
Subscribe for More Information
05:57 EDTORCLSAP CEO says Salesforce unlikely to be acquired, Reuters reports
Subscribe for More Information
May 19, 2015
13:05 EDTORCLSalesforce deal talks may have 'died down,' dealReporter says
Subscribe for More Information
May 18, 2015
20:16 EDTPSUNUrban Outfitters down over 16% after disappointing Q1 results
Urban Oufitters (URBN) is down sharply after reporting first quarter earnings per share and revenue that missed analyst estimates. WHAT'S NEW: Urban Oufitters reported Q1 EPS of 25c on revenue of $739.01M, below consensus expectations of 30c and $758.25M, respectively. Urban Outfitters also reported Q1 comparable retail segment net sales up 4%, with Q1 retail segment net sales increasing 17% at Free People, 5% at Urban Outfitters, and 1% at the Anthropologie Group. Wholesale segment net sales rose 18%. WHAT'S NOTABLE: On its Q1 earnings conference call, Urban Outfitters announced that Urban Outfitters Group CEO Ted Marlow, who oversaw the direction of the namesake brand, would retire at the end of August. While Urban Outfitters did not provide guidance, Urban Outfitters Anthropologie Group CEO David McCreight commented on the Anthropologie brand, "We're expecting we could see Q2 shaping up like Q1 in terms of low single-digit comps. We could also see being in the low-mid-single digit comps. It's hard to tell at this point." ANALYST REACTION: Two analyst firms lowered their respective price targets on Urban Outfitters following the company's earnings report. Sterne Agee, which rates Urban Outfitters a Neutral, lowered its 12-month price target to $34 from $46, noting the company has had trouble getting both its Urban Outfitters and Anthropologie brands to perform at the same time. Cantor, which maintained its Buy rating, lowered its price target to $53 from $54, saying that Anthropologie sales disappointed, but noting that a "later catalog release appears to us to have pushed some sales at Anthropologie into May." PRICE ACTION: Urban Outfitters fell 16.4% to just over $34 in after-hours trading. PEERS: Other publicly traded companies in the space include Abercrombie & Fitch (ANF), American Eagle (AEO), Five Below (FIVE), Pacific Sunwear (PSUN), and Zumiez (ZUMZ).
15:25 EDTSCTYSolarCity management to meet with JPMorgan
Subscribe for More Information
10:18 EDTVCYTVeracyte has Percepta market opportunity above $175M, says Piper Jaffray
Following the publication of results from studies that assessed the performance of Veracyte's Percepta test in lung cancer diagnosis, Piper Jaffray said the data was in line with previous diligence and that it expects the NEJM publication to help drive adoption. The firm, which estimates the initial domestic market opportunity for the test at $177M-$236M, kept its Overweight rating and $13 price target on Veracyte shares.
07:10 EDTVCYTVeracyte announces publication of results from two Percepta trials
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.
07:04 EDTVCYTVeracyte announces publication of results from two studies of Percepta
Subscribe for More Information
05:03 EDTVCYTVeracyte Percepta study published in New England Journal of Medicine
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.
May 17, 2015
16:50 EDTORCLWhite House wavers on backing Google, Oracle in copyright suit, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use